Friday, February 6, 2009

Why Ely Lilly Got Busted For Zyprexa

Not long ago, I got the joy and despair of viewing many documents that were initially not to be seen, by order of the Department of Justice, yet found their way on various locations on the internet- specifically, the website: www.furiousseasons.com.

The documents are, or were, in fact, evidence against Eli Lilly entirely representing their decade of deception promoting and over-medicating others with their drug called Zyprexa, which is in a class of medications called atypical anti-psychotics.

While a new a new molecular entity by definition, this new class called atypical antipsychotics in fact is chemically similar to the older and typical anti-psychotics that existed, such as Haldol, which were available over 50 years ago. In many ways, the older antipsychotics are safer as well as being similar in efficacy compared with the atypicals such as Zyprexa.

Perhaps this is why Eli Lilly did the things they did because they knew Zyprexa caused perhaps more harm than good for those who took the medication. Of the several available atypical anti-psychotics now available, Zyprexa and Clozaril, which was the first atypical anti-psychotic, are believed to have the most toxic adverse events to those who take these two in this class of medications.

Launched in 1996, Eli Lilly did not appear to consider the evidence regarding the adverse effects that may occur to those who take this drug, yet it is believed that there was reason to state by Lilly that there should be caution regarding the use of Zyprexa in those patients prescribed this drug.

With the belief that the maker of Zyprexa is and will be exonerated from any responsibility related to this drug, the promotional campaign was implemented, and has continued ever since.

Evidence of this is a warning letter received by Lilly by the FDA as a warning due to the false and misleading claims Lilly was making about Zyprexa less than 2 months after this drug was approved by the FDA.

At the time Zyprexa was granted approval for marketing, the medication was indicated only for schizophrenia and mania that exists in those with bipolar disorder. Schizophrenia has been defined as a disease that causes the sufferer to deviate from true reality, along with visual and auditory hallucinations.

Bipolar disorder is another mental disorder where the victim alternates from states of heightened neurokinetics to periods of what can be brutal depression for the sufferer.

Eli Lilly, known in recent years by many for their focus on marketing over science or research, greatly desired and hoped that Zyprexa would be a welcome blockbuster for them, which is a medication that exceeds a billion dollars a year in sales as a minimum.

And Eli Lilly appeared to have constructed the obedient and manipulated sales force presumed to be a necessity for this monetary goal to occur without interference.

Yet in actuality, they created a sales force to break federal law from at least the years of 1999 to 2003.

A note about pharmaceutical promotion: pharmaceutical representatives overall are attractive and young individuals with little if any medical knowledge or training, but are determined to have charming personalities along with a perception of obedience related to the pharmaceutical culture, and this is all Eli Lilly in particular wanted from the members of their sales force.

The sales vocation is normally associated to contain members with a high affinity for money, it is believed, so corruptive acts such as off label promotion or overt kickbacks is not typically a consideration of such people, overall, as history has shown.

Therefore, if Eli Lilly’s sales representatives who happen to be instructed to sell Zyprexa for dementia or depression, the orders will likely be followed by such promoters. Or if this sales force is instructed to pay specifically targeted doctors large amounts of money for doing little or no work for this money given to such doctors, it still is not a problem for the sales force to maintain their obedience to their corporate God.

This is the perception of not only myself, but many others as well. Plan of action meetings (POAs) are meetings that are held a few times a year by sizable pharmaceutical corporations to dispense orders to their sales representatives regarding the promotion of their drugs.

A few years after Eli Lilly launched Zyprexa, the maker appeared, according to documents, anxious due to their obvious disappointment regarding the initial prediction that was speculated about the growth of this drug that was not meeting their expectations.

As a result, Eli Lilly implemented POA meetings throughout the nation and shared with the members of their sales force that there is fact a great benefit from a monetary paradigm of implementing ‘seeding trials’. Seeding trials are not unique to Eli Lilly, as others view these trials as a mechanism for generating needed, although fabricated data void of any scientific gain of knowledge (this will be discussed later).

This amazingly was done and implemented afterwards rather overtly. Even more unbelievable is that around this time, the Zyprexa sales force was instructed by Eli Lilly management to seek out clinical trial sites, along with investigators for these trials.

Preferred by Eli Lilly was that the investigators had to either be Eli Lilly prescribing supporters or high volume prescribers. This protocol described was written internally, along with the etiology for performing these sham clinical trials. Anything in writing can be golden, from an illegal situation such as this.

In addition to the clinical trial plan of action of no scientific benefit identified, Eli Lilly instructed its sales force to utilize what was in fact inaccurate promotional material that Eli Lilly gave its Zyprexa sales representatives to be used on their sales calls without exception.

Even though this material was largely if not entirely false and misleading, which was the intent of Eli Lilly, they encouraged their hired promoters that such material was entirely accurate.

To further saturate and corrupt the Zyprexa sales force, they were coerced to blunt assertively what are at this time widely recognized adverse effects of this medication, such as massive weight gain, along with glucose and lipid abnormalities- all of which are dangerous to the user of this medication.

The corrosive promotion of Zyprexa by Eli Lilly continued as this dangerous medical corporation continued their efforts by intentionally altering certain Zyprexa articles by essentially rewriting them, followed by being reviewed internally and not externally by those who are called, 'regulators'.

The purpose was to stimulate what Eli Lilly believed was clearly absent, which was much needed commercial interest related to Zyprexa. It unfortunately worked to a noticeable degree. This is according to what appear to be internal documents from Eli Lilly.

Then it came time to essentially buy benign support groups, if not create what are essentially front groups, in hopes that this would improve the growth of Zyprexa. One example is that Eli Lilly paid the American Diabetes Association for their assistance in obtaining endocrinologist consultants, which is a medical specialty that treats, among other things, diabetes.

To reduce any possibility of an unexpected contingency doing this, they went ahead and hired a good sized team of diabetes educators. In 1999, Eli Lilly altered a Zyprexa report that originally illustrated the glucose problem with the medication, and did so with deliberate intent and reckless disregard for others. Eventually, the American Diabetes Association became quite the critic of Eli Lilly because of their harmful behavior regarding Zyprexa.

A speculative thought regarding the freedom if not acceptance for this type of promotional behavior: there exists amazing alliances between Eli Lilly and the Bush administration have existed as well. George H.W. Bush became an Eli Lilly director after leaving the CIA and lobbied to infect third world countries with Lilly medications.

He also did his best to maximize tax breaks further for this industry that now employs both himself and his political affiliation. In fact, many members of this administration have some connection with Eli Lilly. It seems to be a revolving door issue once again. One could speculate that the Zyprexa campaign continued for so long because of the relationships the maker of the drug had and has with other powerful people.

The next related psychotic tactic (pun somewhat intended) Eli Lilly created was an advisory board paid well by this company to focus on the progressing concerns of Zyprexa. This tactic did work briefly, but did not change the view of the drug by the medical community in any way perceptually regarding their embellished drug.

Understandably, the health care professionals in the medical community began to get vexed and irritated by Eli Lilly’s deceptive and overtly destructive promotional tactics regarding Zyprexa- which included the company’s own speakers that were utilized in the past expressing concerns overtly.

Such events materializing resulted in many ways Eli Lilly being ostracized was because of their disregard for those they are obligated to serve in the medical community, which are those in need of restoration of their health.

Perhaps most disturbing and harmful was the Eli Lilly's intentional holding of crucial safety information related to Zyprexa even before the drug was even approved. For example, Eli Lilly’s Zyprexa representatives were instructed without doubt to neutralize the legitimate concerns doctors may have about Zyprexa, if not outright fear regarding this deadly drug they now perceived as being a clear reality.

The representatives were in agreement of continuing to dodge or neutralize legitimate concerns about Zyprexa, with the promise of Eli Lilly’s management team to fill their wallets more if they maintain obedience regarding this directive that caused harm in the form of such physiological disorders as metabolic syndrome associated with Zyprexa, yet the sales force still denied the association due to the insistence of their employer.

Essentially, the Zyprexa representatives with Eli Lilly were trained, perhaps aggressively, to disarm negative perceptions about Zyprexa, even though these perceptions continuously proved to be valid. This deeply troubled many Zyprexa representatives, as at this point they were aware of the dangers of the drug they were promoting, yet likely continued to do so in order to maintain employment.

Also, and of no great surprise, off label promotion with Zyprexa if not other products by Eli Lilly was a norm within the organization and certainly encouraged by Eli Lilly's management team.

Encouraging doctors to prescribe Zyprexa for unapproved FDA indications are an example. Amazingly, reflecting back on the behavioral flaws by Eli Lilly for quite some time, they did not alter their method of business even though there was a strong perception regarding this company being both aggressive and greedy, and likely criminal in the way they chose to conduct their business.

And depression was not the only off label claim with Zyprexa. Eli Lilly considered such criminal acts as off label promotion as ‘redefining the market’. This is yet another example of their absurdity. The overt demonstration of profits over patients is clearly absurd and inexcusable in any situation.

In the year 2000, Eli Lilly greatly expanded what was called their long term care sales force to increase the utilization of Zyprexa intake in the elderly to nearly 200 specialty sales representatives. This patient population prescribed Zyprexa can be deadly- as Zyprexa is harmful to older citizens- specifically pneumonia and eventual premature death result from Zyprexa intake in this patient population.

The intent was to promote Zyprexa for those certain elderly patients with dementia and Alzheimer’s disease, as a set of symptoms are thought to occur in such patients called, “Sunshiner’s syndrome- which includes elevated agitation and confusion in such patients in the evening hours primarily. The syndrome is vague and non-specific with unknown etiology, yet the intent was to sedate such patients with Zyprexa for this syndrome.

Furthermore, the purpose was to have Zyprexa to be used in these patients to sedate them, a process known as 'snowing'. As a result, each long term care Lilly sales representative increased revenues for their employer more than other sales representatives in different divisions within the organization.

Yet in the year 2002, Eli Lilly was having financial disappointments, which again did not shock many. So to stay in form, they went on a mission to develop speakers to align with them and to not educate others, but to pacify other doctors in hopes that their problems with Zyprexa would disappear.

After the speaker episode, Eli Lilly had the audacity to claim that Zyprexa was indeed the best in the class of atypical antipsychotics. Such a statement appears psychotic, to say the least. And now the market for atypicals is about 5 billion a year, so there seemed to be no end as to what Eli Lilly might try next. Also in this year our FDA called Eli Lilly ‘a sponsor’. I find that a bit disturbing. As disturbing as the covert meetings Eli Lilly had with the FDA as well.

As the new millennium progressed over the next few years, lawsuits became a concern for Eli Lilly regarding Zyprexa. Doing what any responsible corporate entity would most certainly do, the upper management of Eli Lilly had the audacity to blame the media for the way they handled their drug Zyprexa.

Around this time, Eli Lilly needed and did hire a public relations firm because of their image crisis that was likely well-deserved. About this same time, Eli Lilly implemented a nationwide program entitled, “Operation: Restore Confidence”.

I’m not sure how a fully rational and conscious group of Eli Lilly people could create something so ridiculous and unrealistic considering what has materialized due to their crimes. Equally deviating from reality of Eli Lilly’s behavior is that they actually thought they could increase Zyprexa growth by hammering home astronomical efficacy of Zyprexa and continue on the path they have created.

Another failure to add to what has been annotated so far was when Eli Lilly hired an organization called Lifespan Marketing, who colluded with Eli Lilly to create a brand new market establishing Zyprexa as the standard of care. Maybe Eli Lilly needs to adopt a standard of care for itself. This, it is understood, was largely ineffective.

At least one human insider within Eli Lilly wanted to let everyone know he did not, nor will he ever forget his experience as a Zyprexa representative with Eli Lilly for years. His name is Shahram Ahari and he aligned with a non-profit advocacy group called Pharmedout after this experience, which was created due to a state settlement from another pharmaceutical company's wrongdoing.

Sharam spends his days now making others aware of things such as what you have read so far. I’ve spoken with Shahram, and I admire his assistance with others trying to correct this medical mess. He sacrificed much, and continues to do so.

Eli Lilly appears pathologically persistent in frightening ways: next was a national implementation plan of action which focused on training the Zyprexa sales force to use what was called a J.C.P. study to emphasize the numerous off label benefits of Zyprexa.

At the same time, Eli Lilly determined that primary care doctors should be their number one Zyprexa targets for increasing the growth of their drug. With this new focus, the sales force for Zyprexa were somehow convinced to tell doctors that fatigue is really the only side effect that presents itself with Zyprexa use by their patients, which of course is false. Again, citizens are overall not catatonic about such actions if they are aware of them with understanding.

While on this off label role with Zyprexa combined with being void of fair balance regarding presenting this drug to others, Eli Lilly attempted to revive their long term care efforts by taking on Aricept, and Alzheimer’s drug, and encouraged others to switch to Zyprexa.

The reaction for this misbehavior was Zyprexa being removed from Medicaid in 2004, according to documents that are authentic, and are available to others. While Lilly filed with the FDA an indication for Alzheimer’s disease as well as dementia, Zyprexa lacked the evidence to prove that this drug did more good than harm for such patients.

Allan Reier was the Zyprexa product team leader at one point for this drug. He may have developed the unbelievable strategy of visiting psychiatrists to assure them they will not be sued if they prescribe Zyprexa for their patients. Literature and documents prove this strategy was implemented. That in itself illustrates the concern Lilly has about Zyprexa.

So, now we are at a point where Eli Lilly had a flash of reality and preferred no media contact. Gosh, what a surprise. There was also the disclosure of Eli Lilly continuing to create, if not fund, the deceptive front groups to screen others in order to sell more Zyprexa as well.

The next tactical plan from Eli Lilly was to re-implement blunting techniques regarding Zyprexa. My guess is that they dragged this into a week- long meeting with their sales force. This of course included dodging concerns by doctors that they are normally encouraged to partner with, historically.

Such tactical plans of action were associated with such clever names as, ‘Viva Zyprexa’, or Zyprexa Limitless”. Maybe the next one will be ‘Zyprexa Revenue Regression’. Zyprexa for atrophy, maybe?

Another tactic authorized by Eli Lilly was to use those bonafide contract research organizations (CROs) to manufacture safety, health, and outcomes database studies. A deceptive publication plan followed.

CROs are commercial research organizations that include often what may be substandard research investigators to work with the sponsor of such clinical trials.

Eli Lilly, as a sponsor, has the ability to alter aspects of such trials for their own benefit. This was done- as they still encouraged as a result children to consume Zyprexa- near a million of them involved due to an arrangement that Zyprexa will be promoted by Lilly’s ADD drug Strattera.

As stated earlier, previously sealed and damaging documents got exposed at the end of 2006, and are accessible on the internet and some websites, such as www.furiousseasons.com, which is what this article is based upon, overall, these internal documents that appear to be authentic.

Perhaps the documents should have been exposed immediately instead of being held from public view. Perhaps prosecutors should not keep such information from others due to a collusive relationship with such corporations. One may only speculate as to why this occurs.

Eli Lilly makes over 4 billion dollars a year on Zyprexa, and has made close to 40 billion dollars on their drug so far.

Eli Lilly has had to pay well over a billion dollars for Zyprexa damage to others between 2006 and 2007. The company recently paid the largest one-time payment to settle accusations of their wrongdoing regarding Zyprexa at nearly 1.5 billion dollars- with pending cases involving over half of the United States.

I'm sad to say I'm unconvinced this will change their behavior regarding their tactics. Cynical, perhaps, yet I maintain this stance. History proves this is often the case:

"We deeply regret the past actions covered by the misdemeanor plea (1.4 billion dollar settlement with the DOJ). At Lilly, we take seriously our responsibilities to abide by all the laws governing our business practices, and we realize that we have a tremendous responsibility to the patients and healthcare professionals we serve. Every day and with every interaction we strive to operate in a responsible and compliant manner. Doing the right thing is non-negotiable at Lilly, and I remain personally committed to all of us at Lilly maintaining the highest standards of conduct. The company's comprehensive compliance program is an embedded part of the company's culture. These are not just words to us- we continue to implement a range of programs and policies to help ensure that we operate in a manner consistent with all applicable laws and regulations. These programs apply to all parts of our business, and all of our employees are aware of the imperative for them to be models of compliance and of ethical behavior."
------ John C. Lechleiter, C.E.O., Eli Lilly

Psychosis-
One with a personality disorder manifested in aggressive, perverted, criminal, or amoral behavior without empathy or remorse.

Dan Abshear
Author’s note: What has been written is based upon information and belief.

1 comment:

度奉賢張瑞龍傳承LGSUN孫良哲信服台北不婚獨子 臺獨 said...

悉怛多缽怛囉阿門
不淨觀青黃赤白黑

不淨觀(http://www.wretch.cc/blog/mod_cloak2.php黃 DSC-T9 誠實(國自 和-T9 前 是密碼))
是對治淫欲和貪欲很殊勝的方式.
http://big5.jiexieyin.org/show.aspx?id=961&cid=19
http://big5.jiexieyin.org/topicnews.aspx?tid=2
http://big5.jiexieyin.org/list.aspx?cid=20


=>http://www.wretch.cc/album/album.php?id=zycxxcz1234&book=20
www.wretch.cc/blog/zycxxcz1234&article_id=4325607
http://www.wretch.cc/blog/zycxxcz1234&article_id=4325677
::::
搜尋標題及內容: 不淨觀
http://www.wretch.cc/blog/blog.php?id=zycxxcz1234&search=%E4%B8%8D%E6%B7%A8%E8%A7%80&search_title=1&search_content=1
http://www.wretch.cc/blog/zycxxcz1234/4324016
< h3 >*修身觀─不淨觀< /h3 > http://www.wretch.cc/blog/zycxxcz1234/4324018
< h3 >*三種身至念< /h3 >
不淨觀頌(並敘)

佛為貪欲眾生說不淨觀,觀之既久,貪欲即除,可以越愛河而超苦海。余
閒居閱《大智度論》,因取意而為之頌,以此自警,並以警世云。

死想(先作此觀,為下九想張本):有愛皆歸盡,此身寧久長。替他空墮
淚,誰解反思量?

脹想:記得穠華態,俄成□脹軀。眼前年少者,容貌竟何如?

青瘀想:紅白分明相,青黃瘀爛身。請君開眼看,不是兩般人。

壞想:皮肉既墮落,五藏於中現。憑君徹底看,何處堪留戀。

血塗想:無復朱顏在,空餘殷血塗。欲尋妍醜相,形質漸模糊。

膿爛想:腐爛應難睹,腥臊不可聞。豈知膿潰處,蘭麝昔曾熏。

啖想:羊犬食人肉,人曾食犬羊。不知人與畜,誰臭復誰香?

散想:形骸一已散,手足漸移置。諦觀嫵媚姿,畢竟歸何處?

骨想:本是骷髏骨,曾將誑惑人。昔時看是假,今日睹方真。

燒想:火勢既猛烈,殘骸忽無有。試看煙焰中,著得貪心否?

前詩粗示端緒,尚未諦審觀察,復作五言律,以廣之。

死想:所愛竟長別,淒涼不忍看。識才離故體,屍已下空棺。夜火虛堂
冷,秋風素幔寒。勸君身在日,先作死時觀。

脹想:風大鼓其內,須臾□脹加。身如盛水袋,腹似斷藤瓜。垢膩深塗
炭,蠅蛆亂聚沙。曾因薄皮誑,翻悔昔年差。

青瘀想:風日久吹炙,青黃殊可憐。皮乾初爛橘,骨朽半枯椽。耳鼻缺還
在,筋骸斷復連。石人雖不語,對此亦潸然。

壞想:肌膚才脫落,形質便遭傷。瓜裂半開肉,蛇鑽欲出腸。枯藤纏亂
髮,濕蘚爛衣裳。寄語嬋娟子,休將畫糞囊。

血塗想:一片無情血,千秋不起人。淋漓塗宿草,狼藉汙埃塵。莫辨妍媸
相,安知男女身。哀哉癡肉眼,錯認假為真。

膿爛想:薄皮糊破紙,爛肉棄陳羹。膿血從中潰,蠅蛆自外爭。食豬腸易
嘔,洗狗水難清。不是深憎惡,何由斷妄情?

啖想:屍骸遭啖食,方寸少完全。不飽饑鳥腹,難乾饞狗涎。當年空自
愛,此日有誰憐。不若豬羊肉,猶堪值幾錢。

散想:四體忽分散,一身何所從。豈唯姿態失,兼亦姓名空。長短看秋
草,穠纖問晚風。請君高著眼,此事細推窮。

骨想:皮肉已銷鑠,唯餘骨尚存。雨添苔蘚色,水浸土沙痕。牽挽多蟲
蟻,收藏少子孫。風流何處去,愁殺未歸魂。

燒想:烈焰憑枯骨,須臾方熾然。紅飛天際火,黑透樹頭煙。妄念同灰
盡,真心並日懸。欲超生死路,此觀要精研。 [img]bighug[/img]



February 8, 2008
< h3 >*修身觀─不淨觀< /h3 > 言自體不淨者即三十六物。一髮二毛三爪四齒五皮六肉七骨八髓九筋十脈十一脾十二腎十三心十四肝十五肺十六大腸十七小腸十八胃十九胞二十屎二十一尿二十二垢二十三汗二十四淚二十五浩二十六涕二十七唾二十八膿二十九血三十黃三十一白三十二肪三十三三十四腦三十五膜三十六精也。或論本九穴不淨名共相不淨。三十六物名自相不淨云云。又云何第五。終竟不淨者。謂是死後之九想之不淨是也云云。又云何云觀他不淨觀自不淨。答觀他身九相云觀他身不淨。問其他身九相者何。答他身九相者。一死相。二脹相。三瘀青相。四膿爛相。五壞相。六血塗相。七虫噉相。八骨鎖相。九離壞相也。

三十六物:指構成人身之三十六種要素。然關於數目,多有異說。據大明三藏法數卷四十八所舉,三十六物分為外相、身器、內含三類:

(一)外相十二物,髮、毛、爪、齒、眵、淚、涎、唾、屎、尿、垢、汗。

(二)身器十二物,皮、膚、血、肉、筋、脈、骨、髓、肪、膏、腦、膜。

(三)內含十二物,肝、膽、腸、胃、脾、腎、心、肺、生臟、熟臟、赤痰、白痰。

雜阿含經卷四十三則列髮、毛、爪、齒、塵垢、流涎、皮、肉、白骨、筋、脈、心、肝、肺、脾、腎、腸、肚、生臟、熟臟、胞、淚、汗、涕、沫、肪、脂、髓、痰、膿、血、腦、汁、屎、溺等三十六種。南本涅槃經卷二十二(大一二‧七四九中):「見凡夫身,三十六物不淨充滿」故「不淨觀」,即是觀三十六物不淨(自體不淨)。﹝增一阿含經卷二十五、大品般若經卷五、坐禪三昧經卷上﹞p156



(原經文)

優波尼沙陀,即從座起,頂禮佛足,而白佛言:我亦觀佛最初成道。觀不淨相,生大厭離。悟諸色性。以從不淨白骨微塵,歸於虛空。空色二無,成無學道。如來印我名尼沙陀。塵色既盡,妙色密圓。我從色相,得阿羅漢。佛問圓通,如我所證,色因為上。

(整段經文意思)

優波尼沙陀此云塵性,以觀塵性空而得道故。譯曰近少,微細,因等微細分析至極之言也義譯為微細,極至鄰虛(新譯曰極微。色法之最極少分,鄰似虛空者,此為色法之根本 謂諸識色及定中色,無障無礙,似於虛空,而實非虛空,故名鄰虛也),立即從座位上站起來,頂禮(五體投地以吾頂禮尊者之足也)釋迦摩尼佛的腳後,向釋迦摩尼佛報告說道:觀見如來最初成道的時候。作意思惟觀想,一者觀自身之不淨,二者觀他身之不淨。觀自身不淨,有九相:一死想,二脹想,三青瘀想,四膿爛想,五壞想,六血塗想,七蟲噉想,八骨鎖想,九分散想。觀他身有五不淨:一種子不淨,是身以過去之結業為種,現以父母之精血為種。二住處不淨,在母胎不淨之處。三自相不淨,是身具有九孔,常流出唾涕大小便等不淨。四自體不淨,由三十六種之不淨物所合成。五終竟不淨,此身死竟,埋則成土,蟲噉成糞,火燒則為灰,究竟推求,無一淨相,而生起大厭離心(謂我等當觀生死之中,虛假不實,如水上泡,速起速滅,往來流轉,猶如車輪。此身眾苦所集,一切皆是不淨,甚可厭離。當以此心而行懺悔也。)。了悟一切色性。以從不淨觀白骨觀作意思惟觀想,乃至逐步微細分析微塵極至鄰虛塵,分析到最後則歸於虛空。當達到空色二者均歸於空無之境界,便成就斷三界諸惑已盡,證真諦之理,不更要學修之圓滿智慧,阿羅漢之無漏智。如來印證我名叫尼沙陀(此云塵性,以觀塵性空而得道故。譯曰近少,微細,因等微細分析至極之言也義譯為微細,極至鄰虛(新譯曰極微。色法之最極少分,鄰似虛空者,此為色法之根本 謂諸識色及定中色,無障無礙,似於虛空,而實非虛空,故名鄰虛也))。一切微塵及青黃赤白等顯色及男女形色等之染污情識既然滅盡,微妙不可思議色相周密圓融無礙遍一切處。我從作意思惟觀想分析一切色塵中,證得阿羅漢果位。佛問我們,我們最初發心證悟十八界,是以什麼圓融周遍一切處,通達無礙,為修學之所緣? 如以我所證到的而言,我認為以色塵為最上圓通。



+_________________________*
例如以五臟為例,腎屬水,會發黑光,腎臟不好,因土剋水,脾強腎弱,
是脾害腎成病,當止腎病於脾,故以黑氣攝取黃氣,腎病者即能癒好。同
樣道理,脾屬土,會發黃光,脾臟不好係木剋土,肝強脾弱,當止脾病於
肝,以黃氣攝取青氣,脾病則癒好。心屬火,會發紅光,心臟不好,因水
剋火,腎害心成病,因腎強心弱,當止心病於腎,以赤氣攝取黑氣,心病
則癒好。肝屬木,會發青光,肝臟不好,因金剋木,肺害肝成病,因肺強
肝弱,當止肝病於肺,以青氣攝取白氣,肝病則癒好。肺屬金,會發白
光,肺臟不好,因火剋金,心害肺成病,因心強肺弱,當止肺病於心,以
白氣攝取紅氣,肺病則癒好。在基礎篇裏有這些論述,你的哪種臟器有
病,你就可觀想哪種光,是用物性轉你身體的狀況,萬法唯心造,有心人
在本身內臟有毛病時,打坐到最好時機,要觀想:我哪個毛病沒有了,我
那個有毛病的臟器發光了,一天想,二天想,想了一百次、一千次,想不
發光也不行,所以那個病就沒有了。

黑黃青白紅 赤氣攝取黑氣
黑氣攝取黃氣
黃氣攝取青氣
以青氣攝取白氣
白氣攝取紅氣